About the Psoriatic Arthritis Working Group

Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease occurring in 7–42% of patients with psoriasis. Arthritis, enthesitis, dactylitis, spondylitis, and skin disease result in pain, stiffness, reduced mobility, impairment in physical function, and subsequent disability. PsA is now recognized as a disease that can be serious and progressive despite treatment, resulting in significant physical, psychological, functional, and social impairment.

The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set

Dafna Gladman

Dafna Gladman

Co-Chair

Katy Leung

Katy Leung

Co-Chair

Ana-Maria Orbai

Ana-Maria Orbai

Co-Chair

William Tillett

William Tillett

Co-Chair

Anna Antony - Fellow 
Heidi Bertheussen - Patient Research Partner
Niti Goel - Patient Research Partner
Lori Schick - Patient Research Partner

 

Instrument Selection Presentation: Physical function domain for Psoriatic Arthritis (HAQ-DI & SF-36 PF)

OMERACT Endorsed Core Domain Set for Psoriatic Arthritis

Screen Shot 2021-02-23 at 5.53.12 PM

Working Group Members:

William Tillett
Katy Leung
Ana-Maria Orbai
Dafna Gladman
Lori Schick
Heidi Bertheussen
Niti Goel
Anna Antony
Richard Holland
Ashish Matthew
Philip Mease
Robin Christensen
Laura Coates
Alexis Ogdie
Pil Hoejgaard
Walter Maksymowych
MADA
Vibeke Strand

Scroll to Top